A Case of Cutaneous and Systemic Plasmacytosis Treated With Tocilizumab

Cutaneous and systemic plasmacytosis is a rare lymphoproliferative plasma cell disorder characterized by cutaneous lesions, constitutional symptoms, and polyclonal plasma cell infiltrates. Herein, we describe a middle-aged Vietnamese man diagnosed with cutaneous and systemic plasmacytosis who responded to anti–interleukin-6 receptor antibody tocilizumab and has remained in remission for more than 3 years without tocilizumab-related adverse events.